Literature DB >> 7742216

Haemolytic uraemic syndrome: prognostic factors in children over 3 years of age.

C Renaud1, P Niaudet, M F Gagnadoux, M Broyer, R Habib.   

Abstract

Previous studies have shown that age at onset of primary haemolytic uraemic syndrome (HUS) is a feature of prognostic significance, the disease being of much better outcome in paediatric patients younger than 3 years than in older children. In an attempt to find an explanation for such a difference, we analysed the clinical and pathological features of 42 children over 3 years of age who presented with HUS between 1955 and 1990 in our department. On the basis of the presence of a prodromal diarrhoea, we divided our patients into two groups: 21 children presented with the diarrhoea-associated (typical or D+) form of HUS, whereas 21 had the non-diarrhoea-associated (atypical or D-) form. Of the 42 children, 20 (47.5%) progressed to end-stage renal failure. However, our study shows that age at onset of HUS is not a prognostic feature per se. The difference in outcome between children and infants is most likely related to the high incidence of the atypical subset of HUS in children over 3 years, a subset that is very uncommon in infants. The ominous features which characterise this form of the disease are: (1) the absence of a diarrhoeal prodrome, (2) normal urine output, (3) marked proteinuria, (4) hypertension, (5) the occurrence of relapses or recurrences and (6) the presence of widespread and severe arteriolar changes on renal biopsy. The poor prognosis of the atypical form of HUS warrants the use of fresh-frozen plasma infusions and/or plasma exchange as early as possible in the course of the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742216     DOI: 10.1007/BF00858960

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  43 in total

1.  [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia].

Authors:  C GASSER; E GAUTIER; A STECK; R E SIEBENMANN; R OECHSLIN
Journal:  Schweiz Med Wochenschr       Date:  1955-09-20

2.  [Short- and long-term prognosis of the hemolytic-uremic syndrome].

Authors:  F Janssen; P R Potvliege; M Vainsel; H L Vis
Journal:  Arch Fr Pediatr       Date:  1974-01

3.  Immunofluorescent and histologic findings in the hemolytic uremic syndrome.

Authors:  M Gervais; J B Richardson; J Chiu; K N Drummond
Journal:  Pediatrics       Date:  1971-02       Impact factor: 7.124

4.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

5.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Hemolytic uremic syndrome in childhood: renal function ten years later.

Authors:  M Van Dyck; W Proesmans; M Depraetere
Journal:  Clin Nephrol       Date:  1988-03       Impact factor: 0.975

7.  Plasma therapy for severe hemolytic-uremic syndrome in children in Atlantic Canada.

Authors:  M R Ogborn; J F Crocker; D R Barnard
Journal:  CMAJ       Date:  1990-12-15       Impact factor: 8.262

8.  Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. The HUS Italian Study Group.

Authors:  A Caprioli; I Luzzi; F Rosmini; P Pasquini; R Cirrincione; A Gianviti; M C Matteucci; G Rizzoni
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

9.  Changes in the postenteropathic form of the hemolytic uremic syndrome in children.

Authors:  N A Coad; T Marshall; B Rowe; C M Taylor
Journal:  Clin Nephrol       Date:  1991-01       Impact factor: 0.975

10.  Long term renal outcome of childhood haemolytic uraemic syndrome.

Authors:  M M Fitzpatrick; V Shah; R S Trompeter; M J Dillon; T M Barratt
Journal:  BMJ       Date:  1991-08-31
View more
  5 in total

1.  Risk factors for poor renal prognosis in children with hemolytic uremic syndrome.

Authors:  Alessandra Gianviti; Alberto E Tozzi; Laura De Petris; Alfredo Caprioli; Lucilla Ravà; Alberto Edefonti; Gianluigi Ardissino; Giovanni Montini; Graziella Zacchello; Alfonso Ferretti; Carmine Pecoraro; Tommaso De Palo; Angela Caringella; Maurizio Gaido; Rosanna Coppo; Francesco Perfumo; Nunzia Miglietti; Ilse Ratsche; Rosa Penza; Giovambattista Capasso; Silvio Maringhini; Salvatore Li Volti; Carmen Setzu; Marco Pennesi; Alberto Bettinelli; Leopoldo Peratoner; Ivana Pela; Elio Salvaggio; Giuliana Lama; Salvatore Maffei; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2003-10-31       Impact factor: 3.714

Review 2.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

3.  Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.

Authors:  Orly Haskin; Yafa Falush; Miriam Davidovits
Journal:  Pediatr Nephrol       Date:  2019-09-13       Impact factor: 3.714

4.  Hemolytic uremic syndrome: late renal injury and changing incidence-a single centre experience in Canada.

Authors:  Pierre Robitaille; Marie-José Clermont; Aïcha Mérouani; Véronique Phan; Anne-Laure Lapeyraque
Journal:  Scientifica (Cairo)       Date:  2012-12-31

Review 5.  Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.

Authors:  Bodo B Beck; FrancJan van Spronsen; Arjan Diepstra; Rolf M F Berger; Martin Kömhoff
Journal:  Pediatr Nephrol       Date:  2016-06-11       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.